| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CA27.29 |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | N |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CA27.29重组蛋白的假设性参考文献示例(文献为虚构，仅供参考格式)：
1. **文献名称**: *Expression and Purification of Recombinant CA27.29 Protein for Cancer Biomarker Studies*
**作者**: Smith J, Lee R, Garcia M
**摘要**: 本研究报道了利用大肠杆菌系统高效表达和纯化重组CA27.29蛋白的方法，并验证了其与乳腺癌患者血清样本的免疫反应性，为标准化诊断试剂开发奠定基础。
2. **文献名称**: *Clinical Utility of CA27.29 Recombinant Protein in Early-Stage Breast Cancer Detection*
**作者**: Wang Y, Patel S, Kim H
**摘要**: 通过ELISA和免疫组化分析，验证重组CA27.29蛋白作为血清标志物在早期乳腺癌诊断中的敏感性和特异性，结果显示其优于传统CEA检测。
3. **文献名称**: *Immunogenicity of Recombinant CA27.29 Protein in Vaccine Development Against Metastatic Tumors*
**作者**: Müller T, Zhang L, O'Connor D
**摘要**: 探讨重组CA27.29蛋白作为肿瘤疫苗的潜力，动物实验表明其能诱导特异性T细胞应答并抑制小鼠模型中乳腺癌转移。
4. **文献名称**: *Structural Characterization of Recombinant CA27.29 Glycoforms and Their Role in Immune Evasion*
**作者**: Silva F, Nguyen A, Rossi G
**摘要**: 利用质谱和分子动力学模拟解析重组CA27.29的糖基化修饰模式，揭示其通过特定糖链结构逃避免疫监视的机制，为靶向治疗提供新思路。
注：以上文献为示例，实际引用需查询真实数据库(如PubMed)。
CA27.29 recombinant protein is a tumor-associated antigen primarily linked to breast cancer diagnostics and research. It corresponds to the epitope of the polymorphic epithelial mucin (MUC1), a transmembrane glycoprotein encoded by the *MUC1* gene. MUC1 is normally expressed on the apical surface of glandular epithelial cells, where it plays roles in cell signaling and protection. However, in adenocarcinomas—particularly breast, ovarian, and pancreatic cancers—MUC1 becomes aberrantly overexpressed and undergoes altered glycosylation, exposing the protein core, including the CA27.29 epitope. This epitope resides in the tandem repeat region of MUC1’s extracellular domain, characterized by a 20-amino-acid sequence (PDTRPAPGSTAPPAHGVTSA) repeated multiple times.
The CA27.29 recombinant protein is engineered using biotechnological methods, often expressed in mammalian or bacterial systems, to mimic the immunogenic region of MUC1 for research and diagnostic applications. It serves as a critical reagent in immunoassays, such as the CA27.29 blood test, which detects elevated levels of soluble MUC1 fragments in serum to monitor breast cancer recurrence or treatment response. Beyond diagnostics, this recombinant protein is explored in therapeutic development, including MUC1-targeted vaccines and monoclonal antibodies, aiming to harness the immune system against MUC1-expressing tumors.
Research on CA27.29 also focuses on understanding MUC1’s role in oncogenesis, as its overexpression correlates with tumor progression, metastasis, and immune evasion. Despite its clinical utility, CA27.29’s specificity limitations (e.g., false positives in benign conditions) drive ongoing efforts to refine MUC1-based biomarkers and therapies. Overall, CA27.29 recombinant protein remains a pivotal tool in both cancer biology and translational medicine.
×
